论文部分内容阅读
作者旨在研究新型 H_2受体阻滞药尼扎丁(nizatidine)的疗效,并与雷尼替丁作比较,方法选用141例门诊病人,男103例,女38例,年龄18～77岁,经内镜证实为活动性十二指肠溃疡(DU)。随机分成尼扎替丁组和雷尼替丁组,其中3例未完成规定疗程者不列入本研究,故两组各69例。治疗期间未服类固醇、阿司匹林等致溃疡药物,亦未用其它抗溃疡药物。采用双盲对照试验,睡前顿服尼扎替丁300mg 或雷尼替丁300mg。治疗4、8周后作胃镜复查。结果治疗4周后尼扎替丁组84.1%(58/69例)、
The aim of the study was to investigate the efficacy of nizatidine, a new H 2 blocker, and to compare it with ranitidine. METHODS: 141 outpatients, 103 males and 38 females, aged 18-77 years, Endoscopic confirmed as active duodenal ulcer (DU). Randomly divided into nizatidine group and ranitidine group, of which 3 cases did not complete the prescribed course of treatment are not included in this study, so the two groups of 69 cases. During treatment did not take steroids, aspirin and other ulcer drugs, nor with other anti-ulcer drugs. A double-blind, controlled trial of nizatidine 300 mg or ranitidine 300 mg before bedtime. 4,8 weeks after treatment for gastroscopy review. Results After 4 weeks of treatment, 84.1% (58/69) of nizatidine group,